SCHEMBL14136236

SCHEMBL14136236

CC(=O)N1N=C(c2ccc(NS(=O)(=O)c3ccc(Cl)cc3)cc2)CC1c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 2/20 0.69
▸ MAOA P21397 1/20 0.62
▸ MAOB P27338 1/20 0.62
▸ NT5E P21589 1/20 0.60
▸ EGFR P00533 2/20 0.60
▸ KIF11 P52732 1/20 0.60
▸ CA1 P00915 4/20 0.59
▸ CA2 P00918 4/20 0.59
▸ CA9 Q16790 4/20 0.59
▸ CA12 O43570 3/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ RAB9A P51151 2/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ CA4 P22748 1/20 0.58
▸ BCL2 P10415 1/20 0.56
▸ BECN1 Q14457 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ GLA P06280 1/20 0.56
▸ HTT P42858 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133910 0.96 PTGS2 (0.69) PTGS2MAOAMAOBNT5EEGFR
SCHEMBL14136252 0.95 PTGS2 (0.77) PTGS2MAOAMAOBEGFRCA1
SCHEMBL14136237 0.93 NT5E (0.66) PTGS2NT5EEGFRKIF11CA1
SCHEMBL14136239 0.91 PTGS2 (0.71) PTGS2MAOAMAOBEGFRCA1
SCHEMBL14136238 0.91 ACHE (0.69) PTGS2MAOAMAOBNT5EEGFR
SCHEMBL14058064 0.90 PTGS2 (0.70) PTGS2MAOAMAOBNT5EEGFR
SCHEMBL14133398 0.89 MAOA (0.68) PTGS2MAOAMAOBNT5EEGFR
SCHEMBL14136259 0.89 PTGS2 (0.67) PTGS2MAOAMAOBEGFRCA1
SCHEMBL14058025 0.89 NPC1 (0.78) PTGS2MAOAMAOBEGFRCA1
SCHEMBL14133514 0.88 MAOB (0.66) PTGS2MAOAMAOBEGFRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 PTGS2 1275/4885MAOA 4254/4885MAOB 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback